SHPG - Shire plc

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
145.25
-2.57 (-1.74%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close147.82
Open146.84
Bid144.00 x 500
Ask148.08 x 200
Day's Range145.03 - 146.96
52 Week Range139.36 - 192.64
Volume1,078,686
Avg. Volume1,172,201
Market Cap43.07B
Beta1.82
PE Ratio (TTM)64.99
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.92 (0.62%)
Ex-Dividend Date2017-09-07
1y Target EstN/A
Trade prices are not sourced from all markets
  • Why Shire plc (LSE:SHP) Delivered An Inferior ROE Compared To The Industry
    Simply Wall St.5 days ago

    Why Shire plc (LSE:SHP) Delivered An Inferior ROE Compared To The Industry

    Shire plc’s (LSE:SHP) most recent return on equity was a substandard 2.31% relative to its industry performance of 25.47% over the past year. SHP’s results could indicate a relatively inefficientRead More...

  • Shire's New Formulation of Oncaspar Gets CHMP Recommendation
    Zacks6 days ago

    Shire's New Formulation of Oncaspar Gets CHMP Recommendation

    Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar, received CHMP recommendation for approval in EU.

  • Capital Cube12 days ago

    ETFs with exposure to Shire Plc : October 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Shire Plc Here are 5 ETFs with the largest exposure to SHPG-US. Comparing the performance and risk of Shire Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Shire Plc :SHPG-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017
    Capital Cube13 days ago

    Shire Plc :SHPG-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017

    Categories: Yahoo FinanceGet free summary analysis Shire Plc reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 3,822.03 million, Net Earnings of USD 246.41 million. Gross margins narrowed from 58.29% to 57.33% compared to the same period last year, operating (EBITDA) margins now 35.09% from 30.14%. Change in operating cash ... Read more (Read more...)

  • The Wall Street Journal19 days ago

    Shire Alleges Allergan Blocked Drug From Medicare Contracts

    Shire filed an antitrust suit against Allergan, alleging Allergan’s contracts with Medicare Part D drug plans for its Restasis eye drops effectively blocked access to Shire’s rival drug.

  • Reuters20 days ago

    Shire sues Allergan in U.S. over dry eye drug

    In a complaint filed with the federal court in Newark, New Jersey, Shire accused Allergan of violating antitrust laws to preserve its roughly 90 percent share in Medicare prescription drug plans for its older and "clinically inferior" dry eye drug Restasis, and block prescriptions of Shire's rival drug Xiidra. "Quite simply, Allergan has and will continue to use bundled discounts, exclusive dealing, coercion and interference to unlawfully 'block' Shire from competing with it, and to maintain its monopoly in the Part D market at all costs," Shire said, referring to the Medicare drug plans.

  • Reuters20 days ago

    Shire sues Allergan in U.S. over dry eye drug

    Allergan Plc was sued on Monday by Shire Plc for allegedly scheming to block doctors from prescribing its new treatment for dry eye disease. In a complaint filed with the federal court in Newark, New Jersey, Shire accused Allergan of violating antitrust laws to preserve its roughly 90 percent share in Medicare prescription drug plans for its older and "clinically inferior" dry eye drug Restasis, and block prescriptions of Shire's rival drug Xiidra.

  • Should You Sell Shire plc (LSE:SHP) At £37.78?
    Simply Wall St.23 days ago

    Should You Sell Shire plc (LSE:SHP) At £37.78?

    Shire plc (LSE:SHP) trades with a trailing P/E of 65.3x, which is higher than the industry average of 36.1x. While this makes SHP appear like a stock to avoid orRead More...

  • Shire Plc : SHPG-US: Dividend Analysis : September 08th, 2017 (record date) : By the numbers : September 29, 2017
    Capital Cube23 days ago

    Shire Plc : SHPG-US: Dividend Analysis : September 08th, 2017 (record date) : By the numbers : September 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Shire Plc with the following peers – Valeant Pharmaceuticals International Inc, Pfizer Inc., Johnson & Johnson, Eisai Co., Ltd. Sponsored ADR, Sanofi Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, CSPC Pharmaceutical Group Ltd. Sponsored ADR, Impax Laboratories, Inc., Sangamo Therapeutics, Inc. and Novartis AG ... Read more (Read more...)

  • Barrons.com27 days ago

    Why Allergan is Jumping

    Often enough, the departure of a company's chief financial officer is seen as bad news by investors. Why is Allergan gaining when companies like Red Hat (RHT) and Shire (SHPG) have dropped after similar announcements? Chalk it up to Allergan's announcement that it would use its free cash flow to buy back stock instead of on acquisitions, as well as pay down debt and increase the dividend.

  • Is Shire plc (SHPG) a Suitable Value Stock?
    Zackslast month

    Is Shire plc (SHPG) a Suitable Value Stock?

    Shire is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

  • Neos Therapeutics ADHD Drug Adzenys Receives Approval in US
    Zackslast month

    Neos Therapeutics ADHD Drug Adzenys Receives Approval in US

    Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.

  • Market Realistlast month

    What’s Cooperman’s View on Shire?

    Shire was the seventh-largest holding in Cooperman's Omega Advisors’ portfolio in 2Q17, representing nearly 3.5% of total holdings.

  • Top Research Reports for Disney, Kraft Heinz & CVS Health
    Zackslast month

    Top Research Reports for Disney, Kraft Heinz & CVS Health

    Top Research Reports for Disney, Kraft Heinz & CVS Health

  • Alnylam Shares Plunge on Patient Death, Dosing Suspended
    Zackslast month

    Alnylam Shares Plunge on Patient Death, Dosing Suspended

    Alnylam (ALNY) announced suspension of dosing in all ongoing studies on its hemophilia candidate, fitusiran, following a patient's death in a phase II study.

  • Here's Why Shire PLC Stock Fell 10% in August
    Motley Foollast month

    Here's Why Shire PLC Stock Fell 10% in August

    Although the biopharmaceutical giant's more recently launched products did well last quarter, sagging sales of two older drugs made investors nervous.

  • Roche (RHHBY) Hemophilia A Drug Granted Priority Review
    Zacks2 months ago

    Roche (RHHBY) Hemophilia A Drug Granted Priority Review

    Roche Holdings AG (RHHBY) announced that its Biologics License Application (BLA) for hemophilia A candidate, emicizumab has been accepted by the FDA and granted priority review.

  • Barrons.com2 months ago

    UPDATE: Shire: There Goes the CFO!

    Update: I spoke with Shire (SHPG) CFO Jeff Poulton about his decision to leave, and he was quick to dispel any concerns that his departure was about anything except his desire to pursue a new opportunity. Poulton also said that calling Shire a specialty-pharmaceutical company is a misnomer, as an overwhelming percentage of revenue now comes from its orphan drug business, a point raised by analyst Evercore ISI analyst Josh Schimmer, who wrote that Shire has "biotech cash flows with a spec pharma valuation" in a note last week. Shares of Shire have fallen 4% to $139.71 at 1:26 p.m. today.

  • Shire Files Marketing Application for Lifitegrast in Europe
    Zacks2 months ago

    Shire Files Marketing Application for Lifitegrast in Europe

    Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.

  • TheStreet.com2 months ago

    Shire Gains as it Seeks European Approval For Dry Eye Treatment

    The drug would be the first such treatment in Europe.

  • Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View
    Zacks3 months ago

    Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View

    Shire plc (SHPG) product sales soared in the second quarter on the back of legacy Baxalta sales. However, generic competition is expected to negatively impact full year revenues.

  • Shire's ADHD Spinoff Idea Is Shaky
    Bloomberg3 months ago

    Shire's ADHD Spinoff Idea Is Shaky

    Shire PLC's ADHD business has been at its core for years and helped it afford last year's transformative, $35 billion dollar purchase of Baxalta Inc.